Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beraprost sodium for preservation of residual renal function in peritoneal dialysis patients
ChiCTR2000040599Phase 4Completed
- Sponsor
- Tongji Hospital
- Start
- Dec 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of beraprost in end-stage kidney disease (ESKD) (2 arms), sponsored by Tongji Hospital. Primary endpoints: Decline rate of residual renal function, Time to anuria and 1 more. Started Dec 2020; status: completed.
02
Drugs
beraprost
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2000040599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040599.